Funded Project Details - FY2021
|Title:|| Combinatorial Targeting of the Cell Cycle and Key Interacting Pathways in Mesothelioma|
|Congressional District Code:
||Biomedical Laboratory R&D
|| April 2020 -
|FY 2021 Funding Amount:
|Total Award Amount
View full abstract and other project information on NIH RePORTER
Go To NIH RePORTER
The Problem: Mesothelioma is a devastating cancer where the majority of patients will die from their disease. The last significant advance in chemotherapy for mesothelioma was pemetrexed, which was approved by the FDA in 2004. The vast majority of mesothelioma tumors have defects in the cell cycle. Low expression of the CDK4/CDK6 inhibitor p16INK4a has been demonstrated in multiple basic and clinical studies of mesothelioma. A phase III study reported a significant increase in survival in breast...
Questions about the R&D website? Email the Web Team
Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.